Lee Roth

Lee Roth

Auto-generated profile, based on publicly available information

Lee Roth

Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, 19104, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Developmental Biology
Verified
Journal Article
Closed access
EMEfrat Monsonego-Ornan
Efrat Monsonego-Ornan
JKJenia Kosonovsky
Jenia Kosonovsky
ABAvi Bar
Avi Bar
LRLee Roth
Lee Roth
VFVeatriki Fraggi-Rankis
Veatriki Fraggi-Rankis
DSDalit Sela-Donenfeld
Dalit Sela-Donenfeld

3 October 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMattia Lauriola
Mattia Lauriola
YEYehoshua Enuka
Yehoshua Enuka
AZAmit Zeisel
Amit Zeisel
Gabriele D'UvaGabriele D'Uva
Gabriele D'Uva
LRLee Roth
Lee Roth
YYYosef Yarden
Yosef Yarden
Signal transduction by receptor tyrosine kinases (RTKs) and nuclear receptors for steroid hormones is essential for body homeostasis, but the cross-talk between these receptor families is poorly understood. We observed that glucocorticoids inhibit signalling downstream of EGFR, an RTK. The underlying mechanism entails suppression of EGFR’s positive feedback loops and simultaneous triggering of negative feedback loops that normally restrain EGFR. Our studies in mice reveal that the regulation of EGFR’s feedback loops by glucocorticoids translates to circadian control of EGFR signalling: EGFR signals are suppressed by high glucocorticoids during the active phase (night-time in rodents), while EGFR signals are enhanced during the resting phase. Consistent with this pattern, treatment of animals bearing EGFR-driven tumours with a specific kinase inhibitor was more effective if administered during the resting phase of the day, when glucocorticoids are low. These findings support a circadian clock-based paradigm in cancer therapy.

6 December 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MMMaicol Mancini
Maicol Mancini
HGHilah Gal
Hilah Gal
NGNadège Gaborit
Nadège Gaborit
LMLuigi Mazzeo
Luigi Mazzeo
Donatella RomanielloDonatella Romaniello
Donatella Romaniello
YYYosef Yarden
Yosef Yarden
Epidermal growth factor receptor ( EGFR ) mutations identify patients with lung cancer who derive benefit from kinase inhibitors. However, most patients eventually develop resistance, primarily due to the T790M second‐site mutation. Irreversible inhibitors (e.g., osimertinib/AZD9291) inhibit T790M‐EGFR, but several mechanisms, including a third‐site mutation, C797S, confer renewed resistance. We previously reported that a triple mixture of monoclonal antibodies, 3×mAbs, simultaneously targeting EGFR, HER2, and HER3, inhibits T790M‐expressing tumors. We now report that 3×mAbs, including a triplet containing cetuximab and trastuzumab, inhibits C797S‐expressing tumors. Unlike osimertinib, which induces apoptosis, 3×mAbs promotes degradation of the three receptors and induces cellular senescence. Consistent with distinct mechanisms, treatments combining 3×mAbs plus sub‐inhibitory doses of osimertinib synergistically and persistently eliminated tumors. Thus, oligoclonal antibodies, either alone or in combination with kinase inhibitors, might preempt repeated cycles of treatment and rapid emergence of resistance.

30 January 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
LRLee Roth
Lee Roth
SSSwati Srivastava
Swati Srivastava
MLMoshit Lindzen
Moshit Lindzen
ASAldema Sas-Chen
Aldema Sas-Chen
MSMichal Sheffer
Michal Sheffer
YYYosef Yarden
Yosef Yarden
LAD1 coordinates EGF-stimulated changes in the cytoskeleton to support aggressive phenotypes in breast cancers.

12 February 2015 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
HCHadas Cohen‐Dvashi
Hadas Cohen‐Dvashi
NBNir Ben‐Chetrit
Nir Ben‐Chetrit
RRRoslin Russell
Roslin Russell
SCSilvia Carvalho
Silvia Carvalho
MLMattia Lauriola
Mattia Lauriola
YYYosef Yarden
Yosef Yarden
Dissemination of primary tumor cells depends on migratory and invasive attributes. Here, we identify Navigator‐3 ( NAV3 ), a gene frequently mutated or deleted in human tumors, as a regulator of epithelial migration and invasion. Following induction by growth factors, NAV3 localizes to the plus ends of microtubules and enhances their polarized growth. Accordingly, NAV3 depletion trimmed microtubule growth, prolonged growth factor signaling, prevented apoptosis and enhanced random cell migration. Mathematical modeling suggested that NAV3‐depleted cells acquire an advantage in terms of the way they explore their environment. In animal models, silencing NAV3 increased metastasis, whereas ectopic expression of the wild‐type form, unlike expression of two, relatively unstable oncogenic mutants from human tumors, inhibited metastasis. Congruently, analyses of > 2,500 breast and lung cancer patients associated low NAV3 with shorter survival. We propose that NAV3 inhibits breast cancer progression by regulating microtubule dynamics, biasing directionally persistent rather than random migration, and inhibiting locomotion of initiated cells.

30 September 2016 in Oncotarget
Verified
Journal Article
Open access
VGValerio Gelfo
Valerio Gelfo
MRMaria Teresa Rodia
Maria Teresa Rodia
MPMichela Pucci
Michela Pucci
MDMassimiliano Dall’ora
Massimiliano Dall’ora
Spartaco SantiSpartaco Santi
Spartaco Santi
MLMattia Lauriola
Mattia Lauriola
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors